The number of people living with HIV in the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK) continues to increase and is believed to have reached 2.3 million by the end of 2009, 30% more than in 2001. Increases in diagnoses and improved prognosis will lead to an increase in the diagnosed prevalence of HIV, presenting a large market potential for therapeutic products.
Features and benefits
- Gain insight into the market potential, including a robust 10-year epidemiological forecast of diagnosed HIV prevalent cases.
- Understand the key epidemiologic risk factors associated with HIV.
In 2010, Datamonitor estimates that there were nearly 1.1 million diagnosed prevalent cases of HIV in the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK). Between 2010 and 2021, Datamonitor forecasts that diagnosed HIV prevalent cases in the seven major markets will increase by 17%, to 1.3 million cases.
In 2010, the US had the greatest number of prevalent diagnosed HIV ca of all the seven major markets (819,500 cases), or 75% of all diagnosed prevalent cases in the seven major markets. By 2021, the number of prevalent diagnosed HIV cases in the US will increase to 864,300.
In the five major EU markets, there were 267,900 diagnosed prevalent HIV cases in 2010 but will increase to 412,000 by 2021. Among the five EU markets, the UK had the greatest number of prevalent diagnosed HIV cases (75,800 cases) in 2010. Japan had about 12,000 people living with diagnosed HIV in 2010 but this will increase to 18,800 by 2021.
Your key questions answered
- What is the number of people living with diagnosed HIV infection in the US, Japan, France, Germany, Italy, Spain, and the UK?
- How will the HIV patient population change over the next decade in the US, Japan, France, Germany, Italy, Spain, and the UK?
- What are the major risk factors of HIV that drive trends in HIV prevalence and how are they changing?